Elevated Plasma Complement Factors in CRB1-associated Inherited Retinal Dystrophies

Lude Moekotte,1 Joke H. de Boer,1 Sanne Hiddingh,1 Aafke de Ligt,1 Xuan-Thanh-An Nguyen,2 Carel B. Hoyng,3 Chris F. Inglehearn,4 Martin McKibbin,4,5 Tina M. Lamey,6 Jennifer A. Thompson,7 Fred K. Chen,6,7 Terri L. McLaren,6,7 Alaa AlTalbishi,8 Daan M. Panneman,9 Erica G.M. Boonen,9 Sandro Banti,10,11 Béatrice Boquet,12,13 Isabelle Meunier,12,13 Elfride De Baere,14,15 Robert Koenekoop,16 Monika Oldak,18 Carlo Rivolta,19,20,21 Lisa Roberts,22 Raj Ramesar,22 Rasa Strupaitė-Šileikienė,23 Susanne Kohl,24 G. Jane Farrar,25 Marion van Vugt,26 Jessica van Setten,26 Susanne Roosing,9 L. Ingeborgh van den Born,27 Camiel J.F. Boon,2,28 and Maria M. van Genderen,1,29, Jonas J.W. Kuiper1

1 Department of Ophthalmology, University Medical Center Utrecht, Utrecht, the Netherlands
2 Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands
3 Department of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands
4 Division of Molecular Medicine, Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom
5 Department of Ophthalmology, St. James’s University Hospital, Leeds, United Kingdom
6 Centre for Ophthalmology and Visual Science, The University of Western Australia, Perth, Western Australia, Australia
7 Australian Inherited Retinal Disease Registry & DNA Bank, Department of Medical Technology and Physics, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
8 St John of Jerusalem Eye Hospital Group, East Jerusalem, Palestine
9 Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands
10 Telethon Institute of Genetics and Medicine, Pozzuoli, Italy
11 Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy
12 Institute for Neurosciences of Montpellier (INM), University of Montpellier, INSERM, Montpellier, France
13 National Reference Center for Inherited Sensory Diseases, University of Montpellier, CHU, Montpellier, France
14 Department of Biomolecular Medicine, Ghent University, Ghent, Belgium
15 Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
16 McGill University Health Center (MUHC) Research Institute, Montreal, QC, Canada
17 Departments of Paediatric Surgery, Human Genetics, and Adult Ophthalmology, McGill University Health Center, Montreal, QC, Canada
18 Department of Histology and Embryology, Medical University of Warsaw, Warsaw, Poland
19 Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland
20 Department of Ophthalmology, University of Basel, Basel, Switzerland
21 Department of Genetics and Genome Biology, University of Leicester, Leicester, United Kingdom
22 UCT/MRC Precision and Genomic Medicine Research Unit, Division of Human Genetics, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
23 Center of Eye Diseases, Clinic of Ear, Nose, Throat, and Eye Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
24 Institute for Ophthalmic Research, Centre for Ophthalmology, University of Tübingen, Tübingen, Germany
25 The School of Genetics & Microbiology, The University of Dublin Trinity College, Dublin, Ireland
26 Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands
27 Department of Ophthalmology, Het Oogziekenhuis Rotterdam, Rotterdam, the Netherlands
28 Department of Ophthalmology, Amsterdam UMC, Amsterdam, the Netherlands
29 Bartiméus, Diagnostic Centre for complex visual disorders, Zeist, the Netherlands

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Word count:
Word count main text (excl. title page, legends, and references):
Funding: Bartimeus Foundation (LM, JHdB, SH, AdL, XN, LvdB, CB, MMvG, JJWK), VHRN vision health research network and FBC fighting blindness Canada (RK), Swiss National Science Foundation (grant 204285) and European Union (grant EJP-RD19-234, Solve-Ret) (CR)
Abstract

Objective: To determine the profile of inflammation-related proteins and complement system factors in serum of CRB1-associated inherited retinal dystrophies (CRB1-IRDs).

Design: A case-control study.

Subjects, Participants, and/or Controls: A cohort of 30 Dutch CRB1-IRD patients and 29 Dutch healthy controls (HC) (Cohort I), and a second cohort of 123 CRB1-IRD patients from 14 countries and 1292 controls (Cohort II) were used in this study.

Methods: Quantitative 370-plex targeted proteomics in blood plasma and genotyping of the single nucleotide variant (SNV) rs7535263 in the CFH gene.

Main Outcome Measures: Plasma concentrations of inflammation-related proteins and the genotype of the SNV rs7535263.

Results: CRB1-IRD patients showed increased plasma levels of complement system and coagulation cascade proteins compared to healthy controls. Complement Factor I [CFI], Serpin Family D1 [SERPIND1], and Complement Factor H [CFH] were significantly elevated (q<0.05, adjusted for age and sex), which correlated (Pearson’s correlation coefficient >0.6) with higher levels of plasma Complement Component 3 [C3] (q = 0.064). The most enriched pathway in patients was the “Complement cascade” (R-HSA-166658, \( \text{Padj} = P = 3.03 \times 10^{-15} \)). An analysis of the genotype of CFH variant rs7535263, which is in close physical proximity to the CRB1 gene and is associated with other retinal conditions by influencing plasma complement levels, revealed significantly skewed allele distribution specifically in Dutch patients (A allele of rs7535263, odds ratio (OR) [95%CI = 2.85 [1.35-6.02], \( P = 6.19 \times 10^{-3} \)), but not in a global case-control cohort (\( P = 0.12 \)). However, CRB1 missense variants that are common in patients display strong linkage disequilibrium (LD) with rs7535263 in CFH in the UK Biobank (D' = 0.97 for p.(Cys948Tyr); D' = 1.0 for p.(Arg764Cys)), indicating that genetic linkage may influence plasma complement factor levels in CRB1-IRD patients.
Complement factors in CRB1-IRDs

After accounting for the CFH genotype in the proteomic analyses, we also detected significantly elevated plasma levels of Complement Factor H Related 2 [CFHR2] in CRB1-IRD patients (q = 0.04).

Conclusions: CRB1-IRDs are characterized by changes in plasma levels of complement factors and proteins of the innate immune system, which is influenced by common functional variants in the CFH-CFHR locus. This indicates that innate immunity is implicated in CRB1-IRDs.

Keywords: inherited retinal dystrophy, CRB1, proteomics, complement, CFH, inflammation
Complement factors in CRB1-IRDs

Introduction

The Crumbs homolog 1 (CRB1) gene (also known as RP12) is a transmembrane protein that functions in the integrity preservation of the photoreceptor layer of the retina. CRB1 pathogenic variants cause a spectrum of rare autosomal recessive inherited retinal dystrophies (CRB1-IRDs) characterized by photoreceptor cell death and early visual impairment.1–3 There are many pathogenic variants associated with CRB1-IRDs, and the clinical phenotypes vary considerably in severity of disease.1,3 Although some correlation between CRB1 genotype and clinical phenotypes can be found,4 overall there is surprisingly little genotype-phenotype correlation, even among cases with identical pathogenic variants.1,3 Therefore, it has been hypothesized that phenotypic variation among patients may be caused by factors other than the underlying CRB1 pathogenic variants.1

The presence of vitreous inflammation or cystoid macular edema (CME) in some patients with CRB1-IRDs suggests that inflammatory pathways may be involved in the pathophysiology.5,6 Indeed, inflammatory genes and complement factors are upregulated in the retinas of rd8 mice homozygous for a Crb1 gene pathogenic variant.1,5–9 Furthermore, we previously showed that patients with CRB1-IRDs exhibit changes in their peripheral blood T cells and dendritic cells.6,10 These findings suggest that variability of immune responses between patients may contribute to differential clinical phenotypes, but there have been few studies that examine the immune profiles of CRB1-IRD patients.6,10

A way to study immune profiles is by examining blood proteins, which contribute to immune responses and function by modifying the signaling of cytokines, triggering acute-phase reactions, and activating complement cascades. Targeted proteomics allows the accurate quantification of hundreds of blood proteins in patient samples to determine, in-depth, the immune profile of disease and identify disease-related mechanisms.11 This technique has provided insight in the blood proteome of diverse eye conditions such as age-related
Complement factors in CRB1-IRDs

macular degeneration (AMD), retinopathy of prematurity, uveitis, uveal melanoma, and diabetic retinopathy.12–18

In this study, we conducted targeted 370-plex proteomics of blood plasma proteins in CRB1-IRD patients and healthy controls to determine the plasma concentrations of inflammation-related proteins. In the same cohort, and in a validation cohort, we determined the CFH gene variant rs7535263 to test for associations between protein expression and genotype.

Methods

Patients

This study was performed in compliance with the guidelines of the Declaration of Helsinki and has the approval of the local Institutional Review Board (University Medical Center Utrecht (UMCU)). In total, 30 patients were referred to the UMCU from the Amsterdam University Medical Centers, Leiden University Medical Center, Bartiméus Diagnostic Center for complex visual disorders, The Rotterdam Eye Hospital and Rotterdam Ophthalmic Institute, and Groningen University Medical Center for recruitment at the outpatient clinic of the department of Ophthalmology of the UMCU (MEC-14-065). Each patient provided written informed consent before participation and blood collection. The CRB1-IRD diagnosis was established by ophthalmic examination, imaging, full field electroretinography, and next-generation sequencing or whole-exome sequencing. Patients were considered to have a molecularly confirmed CRB1-IRD in cases where they harbored two or more rare functional variants (i.e., disease-causing CRB1 variants, such as missense, deletions, loss-of-function, or splice altering variants) affecting both gene copies of CRB1 (Supplementary Table 1).
We excluded patients with systemic inflammatory conditions at the time of sampling and/or patients that received systemic immunomodulatory treatment. At the day of inclusion, patients were examined by visual acuity measurement, and slit lamp examination was performed by an experienced uveitis specialist for assessment of vitreous cells and vitreous haze.

Next, we obtained blood from 29 anonymous age-matched healthy blood bank donors (HC) with no history of ocular inflammatory disease who gave broad written informed consent at the research blood bank of the University Medical Center Utrecht (The “Mini Donor Dienst”).

**Targeted blood proteomics**

Venous blood samples were collected in EDTA Lavender Top Tubes (#362084, BD Biosciences, Franklin Lakes, USA) and then centrifuged for 10 min (400g) within an hour of blood collection (**Supplementary Table 2**). Plasma was transferred to a Falcon™ 15 mL Conical Centrifuge Tube and centrifuged for 10 min (1500g), after which the cleared plasma was transferred and stored in Micronic 1.4 mL round bottom tubes (#MP32022, Micronic, Lelystad, the Netherlands) at -80 degrees Celsius. For proteomic analysis of plasma, patient and control samples were randomized over three 96 well plates (#72.1980, Sarstedt, Nümbrecht, Germany) and sealed (#232698, Thermo Fisher, Waltham, USA) prior to shipment to the Olink Proteomic facility at the Erasmus Medical Center, Rotterdam, the Netherlands. We used the Olink Explore 384 Inflammation II panel for targeted proteomics of blood plasma. This Olink technology is based on Proximity Extension Assays (PEA) coupled with NGS and is capable of the simultaneous relative quantification of 370 protein analytes.7

**TaqMan® SNP genotyping**

Genomic DNA of 59 peripheral mononuclear blood samples in RLT Plus lysis buffer (#1053393, Qiagen, Hilden, Germany) was isolated with the AllPrep DNA/RNA/miRNA Universal Kit (#80224, Qiagen, Hilden, Germany). Next, we determined the rs7535263
variant with the TaqMan® SNP genotyping technology (#4351379, Thermo Fisher, Waltham, USA). Genotypes were called using QuantStudio 12K Flex software (Thermo Fisher, Waltham, USA). Linkage disequilibrium ($r^2$ or D') data for rs7535263 in the CEU population of the 1000 genomes were obtained with the LDproxy tool with genome build GRCh37 in LDlink. The estimated recombination rate for CEU (build GRCh37) generated by Adam Auton was obtained via the 1000 Genomes ftp site (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/working/20130507_omni_recombination_rates/). We calculated the LD between rs7535263 in CFH and CRB1 missense variants p.(Cys948Tyr) and p.(Arg764Cys) in phased whole-genome sequencing data of ~150,000 individuals of the UK Biobank using the --ld function in plink 2.0. The UK Biobank has ethical approval from North West–Haydock Research Ethics Committee (REC reference: 16/NW/0274). Details of the UK Biobank study have been described in detail previously. This research has been conducted using the UK Biobank Resource under Application Number 24711.

TaqMan® genotyping of rs7535263 was also performed in an independent validation cohort (Cohort II) of 123 CRB1-IRD patients from United Kingdom, Australia, Palestine, Italy, France, Belgium, the Netherlands, Canada, Poland, Switzerland, South Africa, Lithuania, Germany, and Ireland (MEC-2010-359) and 1292 Dutch controls from the amyotrophic lateral sclerosis study. All patients provided written informed consent for genetic testing at the centre of recruitment. CRB1-associated genetic diagnoses were made by targeted gene Sanger sequencing or established recently through RP/LCA smMIPs sequencing. TaqMan® SNP genotyping (#4351379, Thermo Fisher, Waltham, USA) was performed on genomic DNA following the same procedure as described above by the laboratory of the Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.

Statistical analyses
Proteome analyses were performed on Normalized Protein eXpression (NPX) units from the output of the Olink analysis in R and R studio (version 4.2.2) using the Olink® Analyze R package. One protein, TNFSF9, had 13 missing data points and 10 proteins did not pass quality control (Olink assay report). These proteins were removed prior to group analyses. The `prcomp` function of R base was used to perform principal component analysis (PCA). Differential expression analysis was performed using a likelihood ratio test (LRT) with age and sex as covariates in the models and we used the `qvalue` package from Bioconductor to correct P values for multiple testing. Over-representation analysis (or enrichment) was performed on proteins with nominal significant differential expression levels (P<0.05) with the `ClusterProfiler` R package and using the WikiPathways database as a reference. The results were plotted using the `dotplot` function of the `enrichplot` R package and the P-values from enrichment analysis were adjusted with the Benjamini-Hochberg (BH) procedure, using the `p.adjust` function in R base, and P-values (Padj) <0.05 were considered statistically significant. Disease association for rs7535263 was assessed with `Plink` using the Fisher’s exact test and expressed as the odds ratio with a 95% confidence interval. We performed a likelihood ratio test (LRT) to assess the relation between the genotype and the protein expression levels and visualized the results using the `corrplot` R package. Other figures were generated with the `ggplot2` package. The explained variance (R2) by the genotype of rs7535263 of plasma proteins was calculated using the squared Pearson correlation coefficient (r²) using the `cor` function in R base.

Results

Generation of a high-quality plasma proteome of CRB1-IRD patients

To explore the composition of inflammatory mediators in the plasma proteome of CRB1-IRD patients, we conducted 370-plex targeted proteomics using proximity extension assays combined with next-generation sequencing in a cohort of 30 patients and 29 healthy controls. To ensure high-quality data for quantitative proteomic analysis, we first applied a
Complement factors in *CRB1*-IRDs

stringent quality control process. We first filtered out low-quality analytes by removing proximity extension assays that did not pass quality control in all plasma samples, resulting in 358 (97%) proteins that passed this filtering step. We detected no outlier plasma samples as shown by the relatively comparable sample median and sample interquartile range (IQR) as well as *Normalized Protein eXpression* (NPX, the protein expression unit which is in Log2 scale) distribution between plasma samples (**Figure 1A and 1B**). However, nine plasma samples exhibited internal controls deviating >0.3 NPX from the plate median which were also removed from the dataset (**Figure 1B**). Principal component analysis on the 50 remaining plasma samples revealed a moderate plate effect that we mitigated by using the *Combat* algorithm to account for batch effects (**Figure 1C and 1D**). As a result, a high-quality proteomic dataset was generated for downstream analysis.

![Quality control NPX values](image1)

![Sample distributions](image2)

![Before ComBat correction (n=50)](image3)

![After ComBat correction (n=50)](image4)
Complement factors in *CRB1*-IRDs

**Figure 1.** Quality control of plasma proteomic profiling by proximity extension assays combined with next generation sequencing. A) The median and the interquartile range (IQR) of the distribution of Normalized Protein eXpression (NPX) values for each of 59 plasma samples (in blue) measured in this study and internal plate and array controls (in grey). The horizontal and vertical dashed lines indicate +/- 2.5 standard deviations of all sample medians (x-axis) and IQR’s (y-axis). B) The sample-wise distributions of NPX values for the Inflammation II panel. Boxplots of NPX values for each plasma sample along the x-axis and NPX values along the y-axis. The center line represents the median. Plasma samples are colored by “QC_Warning” (Warning = >0.3NPX from the median value of all samples on the plate). C-D) The first two principal components of 50 plasma samples and 359 proteins before and after batch correction with Combat.

**Elevated concentrations of plasma complement factors in CRB1-IRD patients**

We then compared the plasma proteome of patients to controls using linear models that include age and sex (likelihood ratio test). At a false discovery rate of 5% (q<0.05), we detected 10 proteins with significantly different abundance between patients and controls (**Figure 2A** and **Supplementary Table 3**). Among these, elevated levels were observed for Complement Factor I [CFI], Complement factor H [CFH], protein S [PROS1], Serpin family D member 1 [SERPIND1], and A Disintegrin-like And Metalloproteinase with ThromboSpondin type 1 [ADAMTS1] in patients compared to healthy controls (**Figure 2B**). We also detected significantly decreased levels for serine protease 22 [PRSS22] and microfibrillar-associated protein 4 [MFAP4] in CRB1-IRD patients.

The 62 proteins most associated with CRB1-IRD patients (nominal P<0.05) showed overall considerable positive correlation in expression levels, with close clustering of CFI, CFH, C3, and SERPIND1 (**Figure 2C**). These 62 proteins were strongly enriched for pathways involving platelet biology, the complement system and coagulation cascades (**Figure 2D** and **Supplementary Table 4**). In detail, the most enriched pathway was the “Complement cascade” (e.g., Reactome pathway R-HSA-166658, \( P_{adj} = P = 3.03 \times 10^{-15} \), **Figure 2D**). In total, 12/62 CRB1-IRD associated proteins were linked to this pathway including the significantly elevated proteins CFH, CFI, and PROS1. In addition, PROS1 and SERPIND1 were also linked to coagulation pathways (i.e., “Formation of Fibrin Clot (Clotting Cascade)”, ...
Complement factors in CRB1-IRDs

$P_{adj} = P = 4.69 \times 10^{-7}$). Another enriched pathway included the “Extracellular matrix organization” (R-HSA-1474244, $P_{adj} = P = 5.84 \times 10^{-3}$) based on the significantly altered plasma proteins ADAMTS1 and MFAP4 (Supplementary Table 4). Collectively, these results show that elevated levels of complement factors and inflammation-related proteins characterized the plasma proteome of patients with CRB1-IRDs.

Figure 2. Plasma complement and coagulation proteins are associated with CRB1-IRDs. A) Volcano plot showing the $-\log_{10}(P\text{-values})$ versus the Log2(mean NPX difference between groups) in plasma protein concentrations. Red indicates proteins with a significant increase in protein concentration and blue indicates proteins with a significant decrease in protein concentration in patients compared to controls. The dotted line indicates $P<0.05$. B) Scatter plots of the levels of Complement Factor I [CFI], A Disintegrin-like And Metalloproteinase with ThromboSpondin type 1 [ADAMTS1], protein S [PROS1], and Serpin family D member 1
Complement factors in *CRB1*-IRDs

[ SERPIND1] in plasma of patients (orange) and controls (blue). The median and the interquartile range (IQR) of the distribution of Normalized Protein eXpression (NPX) values for each plasma sample is shown. C) Correlation plot of the 62 proteins most associated with *CRB1*-IRDs (*P*<0.05 from differential expression analysis). Red indicates a positive correlation, white indicates no correlation, and blue indicates a negative correlation between plasma protein analytes. D) Dot plot showing the top 10 results from enrichment analysis using the plasma proteins associated with *CRB1*-IRDs as shown in C.

The *CFH* genotype is altered in Dutch *CRB1*-IRD patients

On chromosome 1, the *CRB1* gene is located adjacent to the *CFH-CFHR* locus, which is implicated in other retinal conditions by influencing plasma complement protein levels and other proteins detected in our study. Therefore, we hypothesized that linkage between *CRB1* and the *CFH-CFHR* locus could influence the plasma proteome of *CRB1*-IRD patients. To investigate this, we genotyped the common intronic SNP rs7535263 (LD *r*² = 1.0 with AMD risk variant rs1410996 in CEU population of the 1000 Genomes). The genotype of rs7535263 was shown to have the strongest correlation with the gene expression levels of complement factors H related 1 to 4 (CFHR1-4) in The Genotype-Tissue Expression (GTEx) project and is associated with multiple retinal diseases (e.g., AMD, multifocal choroiditis, and serious chorioretinopathy) as well as with other immune mediators on our array, such as CFP.33–40

The LD signatures of rs7535263 (*r*² and *D’S* with linked SNPs) and genetic recombination rates support that *CRB1* variants and *CFH-CFHR* variants may reside in the same haplotype block (*Figure 3A and 3B*). As expected, the allele frequency of rs7535263 of Dutch controls (A allele of rs7535263 = 0.34) was similar to that of the comparable North-European populations of the 1000 genomes (0.36 in GBR [British in England and Scotland] population). In contrast, the A allele of *CFH*-rs7535263 was significantly higher in frequency in patients compared to controls (A allele of rs7535263, odds ratio (OR) [95%CI = 2.85 [1.35-6.02], *P* = 6.19 × 10⁻³] (*Figure 3C and 3D*). The most common *CRB1* variant in our cohort was the homozygous p.(Met1041Thr) missense variants (*CRB1* c.3122T>C;
Complement factors in *CRB1*-IRDs

p.(Met1041Thr)) found in 11/30 patients (37% of patients) which has been previously linked to a large consanguineous pedigree originating from a genetically isolated population in the Netherlands (Figure 3E and 3F). While this variant is rare in the general European population (allele frequency = 0.00001 for rs62635656 in gnomAD database), the variant is found relatively more common (>1%) in this specific geographical Dutch area (Supplementary Table 1). We suspected that this deviation in allele frequency may therefore be the result of biological relatedness among cases (i.e., founder effect). All patients in our cohort homozygous for p.(Met1041Thr) were also homozygous for the A allele of rs7535263, which results in an excess of homozygotes for the A allele of the *CFH* variant rs7535263 and provides circumstantial evidence that biological relatedness between cases may likely influence our analysis of plasma complement factors. In a validation cohort of 123 *CRB1*-IRD cases from multiple countries and 1292 Dutch control participants the A allele of rs7535263 was not significantly more frequent in patients compared to controls (A allele of rs7535263, odds ratio (OR) [95%CI = 1.24 [0.95-1.61], *P* = 0.12). However, as in the first cohort, a skewed allele frequency was observed for rs7535263 for the most common *CRB1* variant p.(Cys948Tyr), also a common *CRB1* variant in previous reports, which suggests linkage between specific variants of *CRB1* and *CFH*. Data from large population databases such as the UK Biobank (UKB) may allow more accurate LD calculation between missense variants in *CRB1* and rs7535263 in the *CFH* gene. To this end, we used phased whole-genome sequencing data from the UK Biobank from ~150,000 individuals and calculated LD for *CRB1* missense variants. Two *CRB1* missense variants commonly found in *CRB1*-IRD cases with UKB allele frequencies that allow meaningful LD calculations (allele frequency > 0.0001) display strong LD with rs7535263 in *CFH*; the p.(Cys948Tyr) variant is in LD with the G allele of rs7535263 (D’=0.97, UKB) and the p.(Arg764Cys) T allele is in full LD (D’ =1.0 in UKB) with the A allele of rs7535263. Collectively these results confirm our initial observation that patients with *CRB1* missense variants may co-inherit functional variants in the adjacent *CFH* locus, which should be considered in quantitative analysis of plasma complement factors in *CRB1*-IRD patients.
Figure 3. Skewed allelic distribution for a common CFH variant in patients with CRB1-IRDs. A-B) Linkage disequilibrium (r^2 metric left, and D' metric right) for rs7535263 in CEU superpopulation of the 1000 Genomes Project. Genes in the complement factor H (CFH) extended locus and CRB1 are highlighted. C) Allele frequency distribution for rs7535263 in cohort 1 in cases and controls. D) The odds ratio, 95% confidence interval and P-value from Fischer’s exact test for the A allele of rs7535263 in case-control analysis of cohort 1. E) The frequency of each CRB1 pathogenic variant in cohort 1. F) Heatmap of the frequency of patients with rs7535263 genotype and CRB1 Met1041Thr variant dosage in cohort 1.
**CRB1-IRD patients show elevated plasma CFHR2 after adjusting for CFH genotype**

We investigated the effect of rs7535263 on the plasma concentrations of immune mediators in healthy controls. In line with previous studies, the genotype of rs7535263 explained a significant proportion of the plasma levels of several proteins encoded by genes in the extended CFH-CFHR locus, including Complement factor H related protein 2 (CFHR2) ($R^2 = 0.36$), and CFHR4 ($R^2 = 0.24$), but not CFH ($R^2 = 0.003$) (Supplementary Table 5 with $R^2$ values), indicating that the genotype of this SNP may interfere with our analysis of some proteins in CRB1 patients. We therefore repeated our proteomic analysis for cohort 1 while correcting for the genotype of rs7535263 (along with sex and age). This analysis revealed that the association with the 10 significantly altered plasma proteins ($q<0.05$) in our initial group comparison were not significantly influenced by the genotype, such as CFI ($q_{rs7535263} = 0.003$), and CFH ($q_{rs7535263} = 0.06$) (Figure 4A and 4B, Supplementary Table 3) and all 10 remained within an FDR of 7% ($q<0.07$). However, adjusting for rs7535263 revealed additional proteins associated with CRB1-IRDs, most likely by improving statistical power by reducing residual variance. Among these plasma proteins was CFHR2 ($q_{rs7535263} = 0.04$), further supporting dysregulation of complement pathways in CRB1-IRDs (Figure 4A and 4B). Correcting for rs7535263 also revealed significant association ($q_{rs7535263}<0.05$) with the DNA binding protein ZBP1, and RNA helicase DDX39A, which was previously also associated with the genotype of rs7535263 in multifocal choroiditis patients.38

The identified complement factors CFI, CFH, and CFHR2 all target C3, an important downstream effector of the complement system which was also increased in CRB1-IRD patients, albeit at nominal significance ($q = 0.064$) (Figure 4D). Based on the profile of complement factors in our array ($n = 18$), we performed a correlation analysis to identify the factors associated with plasma C3 levels in our cohort. This analysis revealed that CFH and CFI, but not CFHR2, strongly correlated with the levels of plasma C3 (Figure 4C and 4D).
Complement factors in CRB1-IRDs

Figure 4. Elevated CFI and CFH levels correlate with plasma C3 in CRB1-IRDs. A) Results from differential expression analysis before (x-axis) and after (y-axis) corrected for the genotype of rs7535263. The -Log10(P-value) for each protein analyte is shown. Red indicates proteins that became statistically significantly different between cases and controls after adjusting for the genotype of rs7535263 and the color black indicates the 10 significant plasma proteins (q<0.05) in our initial group comparison. Purple highlights plasma proteins involved in complement pathways. The dotted line indicates P<0.05. B) Boxplots showing the levels for complement factor H [CFH] and complement factor H related 2 [CFHR2] in cases and controls in bulk and stratified by the genotype of CFH variant rs7535263. C) Correlation plot of the 18 proteins involved in complement pathways. Red indicates a positive correlation, white indicates no correlation, and blue indicates a negative correlation between plasma protein analytes. D) Boxplot and correlation plots of the levels of Complement Factor I [CFI], CFH, CFHR2, and complement component 3 [C3] in plasma in patients (orange) and controls (blue).

Discussion

In this study, we examined the plasma proteome of patients with CRB1-IRDs, whose levels of inflammation-related proteins and complement factors were notably elevated compared to healthy controls. A remarkable observation was the detection of elevated CFH and CFHR2
proteins in 

CRB1-IRDs because elevated plasma levels of CFHR2 have been linked with other eye conditions, including AMD and multifocal choroiditis patients. CFH/CFHR proteins are all involved in the regulation of the complement component C3, which was supported by our observation of strong correlation between CFI and CFH with C3 in plasma. Our results are also in line with animal models of IRDs (rd10 mice), which show an increase in C3 protein levels and C3 activation, as well as an increase of mRNA of cfh, and cfi in the retina. While C3 is important for complement activation and can cause microglial activation and photoreceptor cell injury, it has also been shown to mediate retina-protective signaling in other murine models of retinal degeneration but will require human trials with (intravitreal) anti-C3 therapy to elucidate its potential as a therapeutic target for CRB1-IRDs. Regardless, the increased levels of complement factors and inflammation-related proteins that we found in patients support immune-mediated pathways involved in CRB1-IRDs.

Among the plasma proteins that were decreased in plasma of CRB1-IRD patients was the extracellular protein MFAP4 that is ubiquitously expressed and plays a role in intracellular interactions and cell adhesion. Macrophages drive local immune responses in retinal degeneration and MFAP4 loss affects macrophage differentiation in animal models. The elevated plasma levels of ADAMTS1 detected in CRB1-IRD patients may be related to angiogenic responses, due to the vascular impairment secondary to degenerative changes in the retina. The ADAMTS1 enzyme is an angiogenic matrix-modifying enzyme that is upregulated by pro-inflammatory conditions in the retinal pigment epithelium (RPE). We also detected elevated levels of PROS1, a protein involved in the homeostasis of RPE. Whole-exome sequencing has previously identified homozygous pathogenic variants in the PROS1 gene as causing retinal dystrophy in two unrelated families, potentially disrupting the vitamin K-dependent activities of PROS1, leading to RPE degradation. Further investigation is needed to determine whether the elevated levels of PROS1 are caused by retinal damage or by other biological events involving PROS1.
Complement factors in CRB1-IRDs

While the plasma proteome may reflect inflammation at the retinal level, it may also be influenced by functional variants in complement factor coding genes. The CRB1 gene is located on chromosome 1 immediately downstream of the CFH locus. SNPs in the CFH locus have been associated with several retinal conditions in which CFH/CFHR proteins were also altered, including AMD, central serous chorioretinopathy, and multifocal choroiditis, indicating that this locus could be an important disease-modifying locus for eye conditions.

Using TaqMan® SNP genotyping technology, we found evidence for skewed distribution of functional variants in the CFH gene which may predispose to altered complement factor levels in CRB1-IRDs or obscure relevant disease associations with plasma proteins, as demonstrated by our work. The significant skewing of the common CFH variants across CRB1 pathogenic variants in our Dutch cohort is likely the result of frequent consanguineous marriages in geographically more isolated populations, such as the strict geographical location of the p.(Met1041Thr) in the Netherlands and predisposes to homozygosity of harmful recessive alleles. Genotype frequencies, Hardy-Weinberg equilibrium assumptions, and allele frequencies can be affected by relatedness and our study demonstrates that addressing relatedness is crucial to ensure the accuracy of genotype-disease relationships and assessment of quantification of the complement factors in CRB1-IRDs and other family-based monogenic conditions. We believe this genetic “confounding” of common variants is currently strongly underappreciated in molecular profiling studies of CRB1-IRDs.

While we show that in a second global cohort there is no association with the CFH/CFHR locus in CRB1 cases in general, data from the well-powered UK Biobank demonstrated linkage between variants in CFH and CRB1. Several key missense variants (e.g., p.(Cys948Tyr)) are nearly exclusively inherited with one of the two alleles of rs7535263, which tag functionally distinct CFH/CFHR haplotypes and predispose to altered composition of plasma complement factors. This linkage is expected from their proximity on the genome and LD signatures in the general population and has important implications for
Complement factors in CRB1-IRDs

Our study demonstrates that complement factor components are involved in CRB1-IRDs, but that relative biological relatedness (i.e., founder effects) between individuals or linkage with functional variants in the CFH locus should be considered in follow-up studies of complement dysregulation in human studies of CRB1-IRDs. While we demonstrate that correcting for the genotype of rs7535263 revealed an otherwise obscured increase in CFHR2 levels in patients, it is not unlikely that additional CFH(R) gene variants that genetically predispose to altered complement factor levels contribute to the pathophysiology of CRB1-IRDs. The limited sample size of our study and the lack of probing for other CFH-related factors encoded by genes upstream of the CRB1 locus (e.g., CFHR1 and CFHR3 levels correlate with genotype of rs7535263 according to gtexportal) may have resulted in an underestimation of the differences in the levels of complement factors in CRB1-IRD patients compared to controls. Many more common variants in immune genes are likely involved in disease-modifying pathways that may influence the severity and disease course of CRB1-IRDs. The use of genome-wide association studies using well defined clinical endpoints, preferably based on microperimetry, may aid in the discovery of these common variants and could improve genotype-phenotype correlations to better predict disease course, and perhaps lead to therapeutic modalities that can alter the disease course. The latter may be also of interest for emerging CRB1 gene-augmentation therapy or mutational correction by allelic substitution via CRISPR/Cas9-mediated homology-directed repair or base editing because these therapeutic approaches are accompanied by immune activation when administered intravitreally or subretinally. It would be important to determine to what extent the inflammatory markers identified in this study may help understand the side effects of gene therapy, such as increased chorioretinal atrophy that has recently been described after gene therapy using voretigene neparvovec for RPE65-associated retinal dystrophies. A major source of plasma complement components is the liver, but complement proteins are also produced and expressed in the retina, as well as by immune cells and various tissues. Complement activation may occur in the retina due to loss of tissue integrity caused by...
CRB1 dysfunction, and modulating the complement system without addressing this primary cause may not have a clinically significant impact on the progression of the disease. Regardless, a complement-targeted therapy may be useful as a combination therapy to minimize adverse reactions from CRB1 gene correcting strategies in retinal degeneration, and potentially even in other gene therapy strategies for IRDs. In future studies, it might be informative to determine the immune profile of patients prior to commencing gene therapy interventions, to determine to what extent complement activation and plasma concentrations influence outcome in patients.

In conclusion, our results implicate the involvement of the complement cascade in CRB1-IRDs. For future research, gene association studies of all SNPs in the genome with a categorization of patients based on disease severity may provide more insight into the pathophysiology of CRB1-IRDs, and IRDs in general.

Acknowledgements

Dr. N.H. ten Dam-van Loon, Dr. J. Ossewaarde-van Norel, and Dr. V. Koopman-Kalinina Ayuso for their assistance performing slit lamp examination and assessment of vitreous cells and vitreous haze on all included patients.
References


Complement factors in CRB1-IRDs


Complement factors in CRB1-IRDs


30. Anon. Chapter 15 Visualization of functional enrichment result | Biomedical Knowledge Mining using GOSemSim and clusterProfiler. Available at: https://yulab-smu.top/biomedical-knowledge-mining/enrichplot.html [Accessed April 4, 2023].


Complement factors in CRB1-IRDs


Complement factors in CRB1-IRDs